title: [Usefulness of nuclear medicine in Erdheim-Chester disease: A Lille experience].
abstract: BACKGROUND
  Erdheim-Chester disease is a rare form of non-langerhans histiocytosis and its etiology is still not well established. The aims of the study were to assess the value of the bone scintigraphy and the18F-FDG PET/CT for the diagnostic and for the latter in the therapeutic evaluation.
  
  
  METHODS
  We retrospectively reviewed 49 patients suspected of Erdheim-Chester disease between 2004 and 2016. Bone scintigraphy was compared with histopathology and PET-CT to conventional morphological examinations and bone scintigraphy. For therapeutic evaluation, thresholds similar to PERCIST 1.0 were used.
  
  
  RESULTS
  Forty-nine bone scintigraphy were evaluated with a sensitivity of 100%, a specificity 97%, a positive predictive value 90% and a negative predictive value of 100%. Eight patients had at least an initial PET-CT. The sensitivity compared to conventional morphological examinations differed from the location but was excellent for orbital, bone and vascular involvements. Specificity was comparable between the different examinations. Six patients treated with interferon®and three with vemurafenib®were followed by PET-CT. PET-CT, in agreement to clinicobiological data, identified 4 partial responses and one complete response with interferon®et two partial responses and one complete response with vemurafenib®.
  
  
  CONCLUSIONS
  Our retrospective study suggests that bone scintigraphy and 18F-FDG PET/CT could be useful in the initial assessment of Erdheim-Chester disease but also for the latter in the therapeutic evaluation.
authors.affiliation: Service de médecine nucléaire, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; Département de biophysique, faculté de médecine Henri-Warembourg, université de Lille 2, 59120 Loos, France. Electronic address: amaury_adens@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Adens
authors.affiliation: Service de médecine nucléaire, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; Département de biophysique, faculté de médecine Henri-Warembourg, université de Lille 2, 59120 Loos, France. Electronic address: pierre.landy@chru-lille.fr.
authors.forename: P
authors.initials: P
authors.lastname: Landy
authors.affiliation: Service de médecine interne, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France. Electronic address: louis.terriou@chru-lille.fr.
authors.forename: L
authors.initials: L
authors.lastname: Terriou
authors.affiliation: Service de médecine nucléaire, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France. Electronic address: clio.baillet@chru-lille.fr.
authors.forename: C
authors.initials: C
authors.lastname: Baillet
authors.affiliation: Service de médecine nucléaire, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France. Electronic address: amandine.beron@chru-lille.fr.
authors.forename: A
authors.initials: A
authors.lastname: Beron
authors.affiliation: Service de médecine interne, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; Département de médecine interne, faculté de médecine Henri-Warembourg, université de Lille 2, 59120 Loos, France. Electronic address: marc.lambert@chru-lille.fr.
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.affiliation: Service de médecine interne, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; Département de médecine interne, faculté de médecine Henri-Warembourg, université de Lille 2, 59120 Loos, France. Electronic address: david.launay@chru-lille.fr.
authors.forename: D
authors.initials: D
authors.lastname: Launay
authors.affiliation: Service de médecine nucléaire, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; Département de biophysique, faculté de médecine Henri-Warembourg, université de Lille 2, 59120 Loos, France. Electronic address: damien.huglo@chru-lille.fr.
authors.forename: D
authors.initials: D
authors.lastname: Huglo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001842:Bone and Bones / Q000000981:diagnostic imaging; D031249:Erdheim-Chester Disease / Q000175:diagnosis*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009683:Nuclear Medicine / Q000379:methods; D000072078:Positron Emission Tomography Computed Tomography; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D055815:Young Adult
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: (18)F-FDG PET/CT; Bone scintigraphy; Erdheim-Chester disease; Interferon-α(®); Interféron-α(®); Maladie d’Erdheim-Chester; Scintigraphie osseuse; TEP-TDM au (18)F-FDG; Vemurafenib(®); Vémurafénib(®)